Compare OMER & DNUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMER | DNUT |
|---|---|---|
| Founded | 1994 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.8M | 672.4M |
| IPO Year | 2008 | 2021 |
| Metric | OMER | DNUT |
|---|---|---|
| Price | $9.27 | $3.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $32.50 | $4.15 |
| AVG Volume (30 Days) | 2.3M | ★ 2.9M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $29,868,000.00 | ★ $1,522,616,000.00 |
| Revenue This Year | N/A | $0.55 |
| Revenue Next Year | $233.22 | $3.59 |
| P/E Ratio | $14.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $2.88 |
| 52 Week High | $17.65 | $5.73 |
| Indicator | OMER | DNUT |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 47.07 |
| Support Level | $9.12 | $3.13 |
| Resistance Level | $11.88 | $3.66 |
| Average True Range (ATR) | 0.92 | 0.22 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 62.40 | 10.34 |
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.